glp-1 cardiovascular outcomes trial august 2025 Emerging Frontiers in Therapeutics: A Comprehensive Evidence Base ( 2025) glp-1 cardiovascular outcomes trial august

The practical takeaway: start allulose low and build slowly

National Library of Medicine) (2025) EGRIFTA SV (tesamorelin) Full Prescribing Information Theratechnologies, Inc

Neither compound is approved by the FDA for any indication in any formulation

Neuropathic and autonomic symptoms improved

Every year, thousands of people (children and adults) are injured, and hundreds die from taking too much of the easy-to-obtain OTC medication used to reduce pain named acetaminophen (initially marketed in 1959 under the brand name Tylenol)

Long-chain n-3 PUFA supplementation reduces plasma bioavailable testosterone in PMOS women, with greater improvements correlating to larger drops in the omega-6:omega-3 ratio (Phelan et al